Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

RecruitingOBSERVATIONAL
Enrollment

3,000

Participants

Timeline

Start Date

September 2, 2019

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Rheumatoid Arthritis (RA)
Interventions
DRUG

Peficitinib

Oral

Trial Locations (47)

Unknown

RECRUITING

Site JP00023, Aichi

RECRUITING

Site JP00005, Akita

RECRUITING

Site JP00002, Aomori

RECRUITING

Site JP00012, Chiba

RECRUITING

Site JP00038, Ehime

RECRUITING

Site JP00018, Fukui

RECRUITING

Site JP00040, Fukuoka

RECRUITING

Site JP00007, Fukushima

RECRUITING

Site JP00021, Gifu

RECRUITING

Site JP00010, Gunma

RECRUITING

Site JP00034, Hiroshima

RECRUITING

Site JP00001, Hokkaido

RECRUITING

Site JP00028, Hyōgo

RECRUITING

Site JP00008, Ibaraki

RECRUITING

Site JP00017, Ishikawa

RECRUITING

Site JP00037, Kagawa

RECRUITING

Site JP00046, Kagoshima

RECRUITING

Site JP00014, Kanagawa

RECRUITING

Site JP00039, Kochi

RECRUITING

Site JP00043, Kumamoto

RECRUITING

Site JP00026, Kyoto

RECRUITING

Site JP00024, Mie

RECRUITING

Site JP00004, Miyagi

RECRUITING

Site JP00045, Miyazaki

RECRUITING

Site JP00020, Nagano

RECRUITING

Site JP00042, Nagasaki

RECRUITING

Site JP00029, Nara

RECRUITING

Site JP00015, Niigata

RECRUITING

Site JP00003, Numakunai

RECRUITING

Site JP00033, Okayama

RECRUITING

Site JP00047, Okinawa

RECRUITING

Site JP00027, Osaka

RECRUITING

Site JP00044, Ōita

RECRUITING

Site JP00041, Saga

RECRUITING

Site JP00011, Saitama

RECRUITING

Site JP00025, Shiga

RECRUITING

Site JP00032, Shimane

RECRUITING

Site JP00022, Shizuoka

RECRUITING

Site JP00009, Tochigi

RECRUITING

Site JP00036, Tokushima

RECRUITING

Site JP00013, Tokyo

RECRUITING

Site JP00031, Tottori

RECRUITING

Site JP00016, Toyama

RECRUITING

Site JP00030, Wakayama

RECRUITING

Site JP00006, Yamagata

RECRUITING

Site JP00035, Yamaguchi

RECRUITING

Site JP00019, Yamanashi

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT03971253 - Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter